Home › Medivation's Xtandi Easily Outperforms Casodex In Key Trial
 

Keywords :   


Medivation's Xtandi Easily Outperforms Casodex In Key Trial

2015-01-23 22:10:48| Biotech - Topix.net

Patients taking Xtandi had a median PFS of 15.7 months compared to 5.8 months in the Casodex group. I have written many articles about Medivation and why I believe their prostate cancer drug Xtandi is going to be a multi-billion dollar drug.

Tags: key trial easily outperforms

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.09Atlantic Tropical Weather Outlook
29.09Eastern North Pacific Tropical Weather Outlook
29.09Hurricane Isaac Graphics
29.09Tropical Storm Joyce Graphics
29.09Hurricane Isaac Forecast Discussion Number 14
29.09Tropical Storm Joyce Forecast Discussion Number 8
29.09Hurricane Isaac Public Advisory Number 14
29.09Summary for Hurricane Isaac (AT5/AL102024)
More »